Boehringer Ingelheim will invest US$185.8 million in Xochimilco

The pharmaceutical group Boehringer Ingelheim reaffirmed its commitment to Mexico through a multi-year investment of US$185.8 million, which will be used to expand and modernize its plant in Xochimilco, Mexico City.

According to the German firm, this complex will become the group's largest tablet production facility, surpassing its sites in Spain, China, Japan, Greece, and Germany.

“From this location and thanks to Mexican talent, the Mexican market will be supplied with antihypertensive and antidiabetic drugs. It will also be exported to more than 40 countries on all continents,” it said.

Augusto Muench, President and CEO of Boehringer Ingelheim in the region, said that the company has believed in Mexico and its people for more than 70 years.

“This investment is a commitment to national talent. Thanks to this project, we are creating 1,800 direct jobs and more than 15,000 indirect jobs,” said the businessman.

He also shared that the goal is to manufacture five billion tablets from Xochimilco.

From the industrial sector, CANIFARMA celebrated this investment as part of a collective effort to strengthen the country's healthcare system through the Plan Mexico program.

Its president, Guillermo Funes, highlighted the pharmaceutical sector's commitment to the transformation the country is undergoing, offering safe, effective, and quality medicines.

He added that the national industry remains committed to research, technological development, manufacturing expansion, and exports.

Parallel to Boehringer Ingelheim's investment, President Claudia Sheinbaum highlighted Mexico's strategic role as a center of innovation and production in health.

On this point, Dr. Kershenobich, head of the Ministry of Health, said that these initiatives demonstrate the transformation that Mexico is undergoing.